Daclizumab  (Synonyms: 达昔单抗; Ro 24-7375)

Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research^[1].

Daclizumab (10 μg/mL) 可显著抑制在抗-CD3/抗-CD28 刺激的人外周血单个核细胞培养体系中活化的人 CD4⁺ T 细胞 (包括初始型 CD45RA⁺CD45RO^- 和记忆型 CD45RA^-CD45RO⁺ 亚群) 的晚期 CD40L 表达^[2]。
Daclizumab (10 μg/mL) 可消除重组 IL-2 (rIL-2) 对 CD40L 表达的恢复作用，证实 CD28 依赖的 CD40L 表达是通过 IL-2R 信号介导的^[2]。
Daclizumab (10 μg/mL) 可抑制经 Th1 极化 (rIL-12、rIL-2 和抗-IL-4 培养) 及 Th2 极化 (rIL-4 和低剂量 rIL-2 培养) 的人 CD4⁺ T 细胞在再次刺激后的 CD40L 表达^[2]。
Daclizumab (10 μg/mL，作用 48 小时) 可抑制分裂过一次的细胞的 CD40L 表达，并降低未分裂细胞的表达水平^[2]。
Daclizumab (10 μg/mL，作用 48-72 小时) 可显著抑制 rIL-12 增强的 PBMC 培养体系中 CD40L 的表达^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Daclizumab (100 μg/只，小鼠，静脉注射，每周一次，共 4 周，于第 0、7、14、21 天给药) 在携带 MET-1 人 T 细胞白血病细胞的 NOD/SCID 小鼠中表现出显著的抗肿瘤功效^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

144.24 kDa

152923-56-3

液体

Colorless to light yellow

达昔单抗；达克珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-2R alpha/CD25 Protein, Human, HEK293, N-His, HY-P7215) can bind Daclizumab. The EC₅₀ for this effect is 16.81 ng/mL.
• 
  Flow Cytometry analysis of Romas cells labelling IL-2Ra/CD25 (red) with Daclizumab (anti-IL-2Ra/CD25) (HY-P108738). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Cohan SL, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.  [Content Brief]

  [2]. Snyder JT, et al. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007 Jun 15;109(12):5399-406.  [Content Brief]

  [3]. Zhang Z, et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood. 2006 Aug 1;108(3):1007-12.  [Content Brief]